Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The dopamine D3 receptor, a quarter century later
Pierre Sokoloff, Bernard Le Foll
European Journal of Neuroscience (2016) Vol. 45, Iss. 1, pp. 2-19
Open Access | Times Cited: 197

Showing 1-25 of 197 citing articles:

<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>
Christoph U. Correll, Nina R. Schooler
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 519-534
Open Access | Times Cited: 553
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update
Valerie Voon, T. Celeste Napier, Michael J. Frank, et al.
The Lancet Neurology (2017) Vol. 16, Iss. 3, pp. 238-250
Open Access | Times Cited: 323
Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes
Stephen M. Stahl
CNS Spectrums (2017) Vol. 22, Iss. 5, pp. 375-384
Open Access | Times Cited: 225
Tobacco and nicotine use
Bernard Le Foll, Megan E. Piper, Christie D. Fowler, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 178
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Stefano Aringhieri, Marco Carli, Shivakumar Kolachalam, et al.
Pharmacology & Therapeutics (2018) Vol. 192, pp. 20-41
Closed Access | Times Cited: 177
Dopamine, Immunity, and Disease
Breana Channer, Stephanie Matt, Emily Nickoloff-Bybel, et al.
Pharmacological Reviews (2022) Vol. 75, Iss. 1, pp. 62-158
Open Access | Times Cited: 146
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
Amanda Krogmann, Luisa Peters, Laura von Hardenberg, et al.
CNS Spectrums (2019) Vol. 24, Iss. S1, pp. 38-69
Open Access | Times Cited: 103
Experience during adolescence shapes brain development: From synapses and networks to normal and pathological behavior
Diana Dow-Edwards, Frank P. MacMaster, Bradley S. Peterson, et al.
Neurotoxicology and Teratology (2019) Vol. 76, pp. 106834-106834
Open Access | Times Cited: 94
Dopaminergic basis for signaling belief updates, but not surprise, and the link to paranoia
Matthew M. Nour, Tarik Dahoun, Philipp Schwartenbeck, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 43
Open Access | Times Cited: 93
Detection of phasic dopamine by D1 and D2 striatal medium spiny neurons
Cédric Yapo, Anu G. Nair, Lorna Clement, et al.
The Journal of Physiology (2017) Vol. 595, Iss. 24, pp. 7451-7475
Open Access | Times Cited: 90
D3 Receptors Regulate Excitability in a Unique Class of Prefrontal Pyramidal Cells
Rebecca L. Clarkson, Alayna T. Liptak, Steven M. Gee, et al.
Journal of Neuroscience (2017) Vol. 37, Iss. 24, pp. 5846-5860
Open Access | Times Cited: 88
Ventral pallidum DRD3 potentiates a pallido-habenular circuit driving accumbal dopamine release and cocaine seeking
Horia Pribiag, Sora Shin, Eric Hou-Jen Wang, et al.
Neuron (2021) Vol. 109, Iss. 13, pp. 2165-2182.e10
Open Access | Times Cited: 65
Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
I. Laszlovszky, Ágota Barabássy, György Németh
Advances in Therapy (2021) Vol. 38, Iss. 7, pp. 3652-3673
Open Access | Times Cited: 59
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Maria Lobo, Thomas Whitehurst, Stephen Kaar, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 324-361
Open Access | Times Cited: 57
Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial
Minghuan Zhu, Zhen-Jing Liu, Qiong-Yue Hu, et al.
Military Medical Research (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 54
Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis
Matthieu Béreau, Vincent Van Waes, Mathieu Servant, et al.
Cells (2023) Vol. 12, Iss. 12, pp. 1599-1599
Open Access | Times Cited: 23
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Letizia Biso, Marco Carli, Marco Scarselli, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 85-85
Open Access | Times Cited: 1
Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome
Sergi Ferré, César Quiroz, Xavier Guitart, et al.
Frontiers in Neuroscience (2018) Vol. 11
Open Access | Times Cited: 81
Modeling the development of drug addiction in male and female animals
Wendy J. Lynch
Pharmacology Biochemistry and Behavior (2017) Vol. 164, pp. 50-61
Open Access | Times Cited: 71
Current Concepts on the Physiopathological Relevance of Dopaminergic Receptors
Ada Ledonne, Nicola Biagio Mercuri
Frontiers in Cellular Neuroscience (2017) Vol. 11
Open Access | Times Cited: 70
Molecular basis of dopamine replacement therapy and its side effects in Parkinson’s disease
Hana You, Louise‐Laure Mariani, Graziella Mangone, et al.
Cell and Tissue Research (2018) Vol. 373, Iss. 1, pp. 111-135
Closed Access | Times Cited: 70
Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects
Zhi-Bing You, Guo-Hua Bi, Ewa Galaj, et al.
Neuropsychopharmacology (2018) Vol. 44, Iss. 8, pp. 1415-1424
Open Access | Times Cited: 70
Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions
Carmine Tomasetti, Felice Iasevoli, Elisabetta Filomena Buonaguro, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 1, pp. 135-135
Open Access | Times Cited: 66
Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine
Chloe J. Jordan, Jianjing Cao, Amy Hauck Newman, et al.
Neuropharmacology (2019) Vol. 158, pp. 107609-107609
Open Access | Times Cited: 62
The highly selective dopamine D R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents
Chloe J. Jordan, Bree A. Humburg, M. S. RICE, et al.
Neuropharmacology (2019) Vol. 158, pp. 107597-107597
Open Access | Times Cited: 62
Page 1 - Next Page

Scroll to top